Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product, PROCYSBI delayed-release capsules, received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the EC, as an orphan medicinal product for the management of nephropathic cystinosis in the EU. Its pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. It has product candidates in clinical development designed to potentially treat HD, NASH in children, Leigh syndrome and other mitochondrial disorders and ALDH2. Its preclinical programs are based upon bioengineered drug candidates that are designed to target cancer and other diseases.